Janice McCourt - 08 Nov 2022 Form 4 Insider Report for Comera Life Sciences Holdings, Inc.

Role
Chief Business Officer
Signature
/s/ Ryan M. Rourke Reed, Attorney-in-Fact
Issuer symbol
CMRA on OTC
Transactions as of
08 Nov 2022
Net transactions value
$0
Form type
4
Filing time
09 Nov 2022, 15:19:03 UTC
Previous filing
09 Nov 2022
Next filing
16 Oct 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMRA Stock Option (Right to Purchase) Award $0 +150,000 $0.000000 150,000 08 Nov 2022 Common Stock 150,000 $1.36 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option shall vest over four (4) years, with twenty-five percent (25%) of the shares of Common Stock underlying the option vesting on November 1, 2023 and the remainder vesting in equal monthly installments thereafter.